14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
KPRX vs NMAD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Kiora Pharmaceuticals, Inc. (KPRX) is the stronger overall head-to-head candidate over NMAD (NMAD) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). KPRX carries a Unified Composite Score of 47.5/100 (HOLD) at $0.72 (1.7x Forward P/E, -890.2% operating margin), whereas NMAD carries 47.9/100 (HOLD) at $2.56 (N/M Forward P/E, N/A operating margin).
Technical & Structure Timing Caution: KPRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 13.7); meanwhile NMAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KPRX vs NMAD. Trailing 12-month operating profitability (KPRX -890.2% vs NMAD N/A) and valuation multiples (KPRX 1.7x vs NMAD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ KPRX vs NMAD Key Questions & Quantitative Answers
As of Nov 20, 2026, Kiora Pharmaceuticals, Inc. (KPRX) is the stronger overall head-to-head candidate over NMAD (NMAD) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). KPRX carries a Unified Composite Score of 47.5/100 (HOLD) at $0.72 (1.7x Forward P/E, -890.2% operating margin), whereas NMAD carries 47.9/100 (HOLD) at $2.56 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: KPRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 13.7); meanwhile NMAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KPRX leads the Growth & Scale pillar: KPRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (N/A gross margin, -890.2% operating margin), compared with NMAD at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, KPRX generates $1.0M in USD-normalized revenue versus N/A for NMAD. In operating R&D and SG&A reinvestment, KPRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NMAD.
KPRX screens cheaper on headline valuation multiples. KPRX trades at 1.7x Forward P/E, 1.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas NMAD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KPRX (-67.7% ROE) versus NMAD (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, KPRX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.62β · 126% Vol realized risk). By comparison, NMAD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.52β · 173% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.